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SUMMARY: The administration of microencapsulated drug in a matrix acid poly(lactic-co-glycolic acid) (PLGA) by intramuscular
(IM) in humans has been approved by the FDA for various applications though it is not clear what effect they have on the morphological
parameters of muscle tissue. The aim of this study was to analyze the morphological changes in the skeletal muscle tissue with their use.
We used 12 adult female Sprague Dawley rats (Rattus novergicus) that were injected into their right gastrocnemius muscle belly with:
sterile vehicle solution (G1, n = 4), 0.5 mg PLGA microparticle (G2, n = 4) and 0.75 mg PLGA microparticle (G3, n = 4), both dissolved
in a sterile vehicle solution. At 14 days post injection the number and diameter of muscle fibers, the level of inflammation and histology
appearance in terms of organization of muscle fibers, cellular distribution, tissue morphology and the presence of polymer waste were
determined and the results between the groups compared. The administration of the compound in a single dose did not alter the morphometric
parameters (number and diameter of muscle fibers) despite generating a mild inflammation in the tissue associated with the presence of
polymeric residues, suggesting that the PLGA microparticles were well tolerated by the muscle tissue at concentrations tested (0.5 and
0.75 mg).
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INTRODUCTION
The remarkable progress in biotechnology has
contributed to the development of new drug delivery systems
that increase the pharmacological effect and reduces side
effects. The drug delivery systems commonly used are based
on chemical modification of biomolecules with polyethylene
glycol (PEGylation) by encapsulating the molecules in lipid
(liposomes) or polymeric systems (microparticles) (Okada
& Toguchi, 1995). The best-known polymeric substances
are poly(e-caprolactone), poly(lactic acid) and biodegradable
aliphatic polyesters of hydroxy-functional acid as the
poly(lactic-co-glycolic acid) (PLGA). The latter offers many
advantages for drug delivery, such as reduced frequency of
administration, reduced total dose required, decrease in
adverse effects and, most importantly the controlled release
of drugs in the treatment period desired, which can range
from hours, weeks or months depending on the charac-
teristics of the microspheres and the route of administration,
in particular, the intramuscular (IM) route, which is the most
used. The PGLA as the polymer matrix for micro-
encapsulation of drugs has shown low toxicity, because it
undergoes non-enzymatic hydrolysis of lactic and glycolic
acids, which are metabolized to carbon dioxide and water
and therefore harmless to the tissues (Tamber et al., 2005).
According to Kohane et al. (2002) and Colombo et
al. (2004), the polymeric microparticles are harmful because
they can cause inflammation, which depends on the nature
of the material, particle size and type of tissue that is
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administered. For Haining et al. (2004) only particles less
than 5–10 microns may be phagocytosed. The polymer’s
molecular weight also affects the length of time the tissue
may affect the kinetics of drug release, as it is a determinant
of the inflammatory response (Kohane et al., 2006). The
FDA (Food and Drug Administration) in the United States
has approved the administration of microencapsulated drugs
in a PLGA matrix via IM in humans since 1989 for controlled
drug release (Putney & Burke, 1998; Bronzino, 2000; Jain,
2009, 2011) in various applications. However, the effect of
PLGA matrices on the morphological parameters of muscle
tissue is not clear.
With this background, the objective of this study was
to analyze the morphological changes in skeletal muscle
tissue in terms of number, diameter and distribution of
skeletal muscle fibers in Sprague Dawley rats subjected to a
single IM injection of biodegradable PLGA microparticles
as a system of drug delivery.
MATERIAL AND METHOD
We used poly(D,L-lactide-co-glycolide) with a 50:50
monomer ratio, ester-terminated and a viscosity 0.26–0.54
dl/g was purchased from Lactel Absorbable Polymers
(Pelham, AL, USA). The poly(vinyl-alcohol) (PVA) was 87–
90% hydrolyzed, average mol. Wt. of 30,000–70,000 Sigma-
Aldrich (St. Louis, MO, USA). Dichloromethane (DCM)
was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Animals. We used 12 female Sprague Dawley (Rattus
novergicus) healthy rats, between 250–300 g, maintained in
the animal facility of the Universidad de Talca. These
arrangements were maintained with light/dark cycle of 12/
12 hours at room temperature 22 ± 21 °C and humidity of
60 ± 10%, fed with commercial pellets and water ad libitum
throughout the experiment. The animals were treated in
compliance with the protocol of bioethics adopted by the
Universidad de Talca, in accordance with the "Guide for Care
and Use of Laboratory Animals" published by the U.S.
National Institutes of Health (NIH Publication no. 85-23,
http://grants.nih.gov/grants/olaw/olaw.htm).
Procedures
Preparation of microparticles. PLGA microparticles (MPs)
were prepared by double emulsion-evaporation method (w/
o/w). In the first emulsion (w/o)  0.4 ml of double distilled
water solution was added into 1 mL of DCM containing 25
mg of PLGA, using a high-speed homogenizer which was
emulsified at 35,000 rpm (Thermo Fisher Scientific,
Waltham, MA) Ultra-Turrax system. The second emulsion
(w/o/w) was mixed with 2 mL of PVA 1% (1 mg/mL) and
emulsified by the same system. The particles were stirred
(orbital shaker at 100 rpm) at room temperature overnight
for the solvent evaporation. The microparticles were then
collected by filtration. Once sieved, the microparticles were
lyophilized and stored at -20 ºC.
Size and morphology of the microparticles
characterization. The determination of the diameters of
microparticles was made by analysis of images obtained by
confocal microscopy and processed in the LSM Image
Examiner software.
The morphology of PLGA microparticles was
analyzed with scanning electron microscopy (SEM) on a
Zeiss DSM 960 microscope equipped with a backscattered
electron detector. The samples were lyophilized and
deposited on a 300-mesh carbon-coated copper grid that had
been previously hydrophilized under UV light (Electron
Microscopy Sciences, Hat- field, PA) and coated with carbon,
prior to examination.
Experimental procedure. The animals were randomly
assigned to form study groups as follows:
Group 1 (G1): control injected with sterile vehicle solution
(n = 4)
Group 2 (G2): experimental; injected with 0.5 mg of PLGA
microparticles in a sterile vehicle solution (n = 4).
Group 3 (G3): experimental; injected with 0.75 mg of PLGA
microparticles in a sterile vehicle solution (n = 4).
The dilution and homogenization of the
microparticles in the vehicle solution for G2 and G3 groups
was made with a stirrer for 15 seconds prior administration.
The rats were injected intramuscularly with a single
puncture (day 0), using a disposable 1 ml syringe graduated
with a 20G needle on the right gastrocnemius muscle. The
puncture site was marked and the entire solution was
deposited  in the fleshy portion of the muscle. The animals
of all groups were kept in care according to individual ani-
mal management protocols for this research.
On day 14 post injection, rats of all the groups were
anesthetized with ether and underwent euthanasia by cervi-
cal dislocation.
Sampling and histological processing. All samples were
directly fixed in buffered formalin, embedded in paraffin
and routinely processed for hematoxylin-eosin staining on
5-mm cross sections selected at random with four sheets for
each piece, which were observed consistently through
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magnification at 100X using an Olympus CX21 microscope (Olympus ®)
and analyzed by MicroImaging Software.
Morphometric parameters:
- Number of muscle fibers per mm2 is defined as the total number of muscle
fibers that are recorded in an area of 1 mm2 with an increase of 100X.
- Diameter of muscle fibers is defined as the diameter of the muscle fiber in
the cross section, expressed in microns (µm).
Based on these parameters descriptive statistics (mean, standard
deviation) were obtained and the differences were evaluated by one-way
ANOVA test, testing the equality of the variances by the Bartlett's test. In
all the cases, the significance was p < 0.05.
Inflammatory Response. The degree of inflammatory response was
evaluated histologically according to the system established by Setzen &
Williams (1997).
Histology. Morphological changes in organization of the muscle fibers and
cellular distribution and tissue morphology were analyzed. The presence of
microscopic polymeric residues, which were defined as any mass, at least
partially, composed of microparticles was also observed.
RESULTS
Our results showed that the
size (diameter, mm) of PLGA
microparticles  was 1.9 ± 0.6 (mm),
and normal particle size
distribution with a range betwen
0.7-3.7 (mm) as shown the Figure
1.
The TEM images showed
polymeric spherical microosized
particles with smooth surface (Fig.
2).
The average number of
muscle fibers counted in the three
groups was similar, although the
variance was significantly different
(Bartlett test p = 0.0375), the
ANOVA p value was 0.9454. Table
I shows the descriptive statistics for
the variable number of muscle
fibers per mm2. Table II shows the
results for the variable diameter of
muscle fibers. When the means are Fig. 2. TEM image of PLGA microparticles (scale 20 µm).
Fig. 1. Size distribution of PLGA microparticles
obtained by confocal microscopy.
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G1 G2 G3
Minimum 19.0 18.0 18.0
Maximum 20.0 20.0 20.0
Mean 19.5 19.0 18.75
SD 0.57 0.81 0.95
G1 G2 G3
Minimum 589.2 589.2 600.8
Maximum 642.5 646.4 641.3
Mean 623.8 625.0 626.0
SD 14.54 16.52 11.03
Table I. Descriptive statistics of the number of fibers per
mm2 in the total sample (100x).
Table II. Descriptive statistics for the variable diameter of
muscle fibers. The values are expressed in microns.
not significant there are differences between the groups
(ANOVA p = 0.8597).
No inflammatory response was found in G1, whereas
G2 and G3 showed a mild inflammatory response in all the
samples.
In all the groups, muscle fibers were observed with a
uniform architecture, well-established location with eccentric
nuclei, similar sizes and regular distribution of fibers.
Similarly, there were no central core muscle fibers (muscle
fibers youth) (Figs. 3 A, B and C). In groups injected with
microparticles (G3 and G4), the connective tissue showed a
regular pattern, but with the mild inflammatory infiltrate, in
which macrophages and lymphocytes were predominant
isolates. There were no areas of fibrosis or necrosis (Fig. 4),
but in all cases, polymeric residues were distributed and
observed in isolation in the connective tissue surrounded by
inflammatory infiltrate (Fig. 5).
Fig. 3. Gastrocnemius muscle of rat (100x increase) there is a uniform tissue structure with eccentric nuclei location, similar diameters
and regular distribution of fibers. A: G1: B: G2; C: G3.
Fig. 4. Inflammatory response and muscle response 2 weeks after injection. Reaction of PLGA microparticles in the adjacent connective
tissue  showed mild inflammatory infiltrate without areas of fibrosis or necrosis. A (40X): G2, B (40X): G3
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DISCUSSION
In this study, we evaluated the response of striated skeletal
muscle tissue to the application of PLGA microspheres for
sustained release. Our results show that the administration of the
compound in a single dose does not alter the morphometric
parameters (number and diameter of muscle fibers) despite
generating a mild inflammation in the tissue associated with the
presence of microscopic polymer waste. This reaction is quite safe
in the muscle tissue, probably due to the PLGA matrix degradation
that occurs by a uniform breaking of their bonds without the
involvement of enzymatic activity. As it is a process of hydrolysis,
the degradation of the PLGA lactic and glycolic acid that enter
the tricarboxylic acid pathway is metabolized and eliminated from
the body as carbon dioxide and water (Giunchedi et al., 1998;
Jain, 2000).
For Jang & Shea (2006), IM injection of polymeric
microspheres loaded with plasmid DNA causes foreign body
reaction characterized by an initial inflammatory infiltrate
composed of neutrophils and macrophages. In this sense, Kohane
& Langer (2010) indicate that polymeric microparticles are inert
and cause no tissue reaction that coincides with acute inflammation
histologically and it does not differ considerably from muscle tissue
response to conventional drug administration via IM. However,
the presence of waste for more than two weeks induces changes
in the composition of inflammatory cells to include macrophages
and lymphocytes. Of course, based on size, the particles can in-
duce the formation of foreign body giant cells that are surrounded
by a fibrous capsule of fibroblasts. In another model, Horie et al.
(2010) observed no significant presence of inflammatory cells in
the middle ear mucosa of pigs after local application of
PGLA microparticles loaded with lidocaine in the cochlea
for the treatment of tinnitus.
Rungseevijitprapa et al. (2008) investigated the
potential myotoxicity of the solvents used in the
preparation of polymer solutions, emulsions, solvents and
formulations with different proportions of phase for the
formation of micro-systems in vitro and in vivo in skeletal
muscle, confirming good biocompatibility of the muscle
to PLGA formulations.
On the other hand, histological analysis of muscles
injected with microspheres found no areas of fibrosis or
necrosis. In addition, there were no young muscle fibers,
which according to Parra et al. (2007) reflect the tissue
regenerative activity, inferred by its absence, indicating
that there was no recent tissue damage.
In all rats injected with micro-PLGA showed the
presence of polymeric residues isolated from adjacent
connective tissue. These results agree with the study of
Kohane et al. (2002), who observed the presence of
isolated microspheres deposits surrounded by foreign
body giant cells two weeks after injection. According
to Jang & Shea, the distribution of the microparticles
in the tissue varies depending on the polymer’s
molecular weight. At two days post injection, the
microspheres of high and low molecular weight were
found in clusters within the tissue occupying regions
and ranging in size from about 0.2 to 1.3 mm. However,
at 50 days post injection, microspheres with high
molecular weight builds up in long clusters, while low
molecular weight microspheres were distributed along
the injection site in small clusters. Furthermore, the size
of the microparticles allowed a lower inflammatory
response. In our study, we used a formulation of PLGA
microparticles between 0.5 and 10 microns in diameter
confirming the findings of Haining et al., who claimed
that particle size determines in part the nature of the
inflammatory response. Our particles, between 0.7-3.7
microns can be easily degraded, while those of a larger
size are not necessary for the processes of phagocytosis.
The mild inflammatory response observed in this
study, together with the absence of the foreign body
reaction and maintenance of the morphometric parameters
suggest that the PLGA microspheres are well tolerated by
the muscle tissue at concentrations of 0.5 and 0.75 mg.
This finding allows its use for injectable intramuscular
administration, permitting more irritating substances and
managing higher volumes of drugs than that of the
intravenous route.
Fig. 5. Tissue reaction to PLGA microparticles 2 weeks after injection.
Polymer residues are observed in the adjacent connective tissue
associated with a mild inflammatory infiltrate (B, 4X: G3).
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RESUMEN: La administración de fármacos encapsulados en micropartículas de ácido poli-láctico/glicólico (PLGA) por vía intramuscular
(IM) ha sido aprobada por FDA para su uso en seres humanos con variadas aplicaciones, no estando claro el efecto que tienen sobre los
parámetros morfológicos del tejido muscular. El objetivo de este estudio fue analizar los cambios morfológicos en el tejido muscular esquelético.
Se utilizaron 12 ratas (Rattus novergicus) hembras de la cepa Sprague Dawley, las cuales fueron inyectadas en el vientre del músculo gastrocnemio
derecho con: solución vehículo estéril (G1, n=4) y con micropartículas 0,5 mg (G2, n=4) y 0,75 mg de PLGA (G3, n=4) ambas disueltas en
solución vehículo estéril. A los 14 días post inyección se determinó el número y diámetro de fibras musculares, el nivel de inflamación y el
aspecto histológico en términos de organización de fibras musculares, así como la distribución y morfología celular del tejido conjuntivo y
presencia de residuos poliméricos, comparándose los resultados entre los grupos de estudio. La administración del compuesto en una sola dosis
no modificó los parámetros morfométricos (número y diámetro de las fibras musculares), a pesar de generar una inflamación leve en el tejido,
asociado a la presencia de residuos poliméricos, lo que sugiere que microesferas de PLGA son bien toleradas por el tejido muscular en las
concentraciones probadas (0,5 and 0,75 mg).
PALABRAS CLAVE: Músculo esquelético; Liberación de fármacos; Micropartículas poliméricas; PLGA.
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